Recently, the efficacy of cyclin-dependent kinase 4/6 (CDK 4/6) inhibitors as adjuvant therapy was demonstrated in patients with HR-positive, HER2-negative, node-positive high-risk early breast cancer (EBC) in the monarchE trial [3]. Here, ERBB2 is linked to breast carcinoma.